Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075810 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1 study of Breast Cancer and Breast Neoplasm, sponsored by MBQ Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06075810 is a Phase 1 study of Breast Cancer and Breast Neoplasm that is actively recruiting participants, run by MBQ Pharma. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06075810, a Phase 1 study of Breast Cancer and Breast Neoplasm, is actively recruiting participants, sponsored by MBQ Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Conditions Studied
Interventions
- DRUG MBQ-167
Study Locations (4)
California
- Precision Next Gen Oncology & Research Center - Beverly Hills
Florida
- Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI - Sarasota
Tennessee
- Sarah Cannon Research Institute/SCRI - Nashville
Other
- FDI Clinical Research - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06075810
The ClinicalTrials.gov registry entry for NCT06075810 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is MBQ Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MBQ-167 is the first listed.
NCT06075810 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06075810 about?
NCT06075810 is a clinical study titled "A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer". A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
What is the current status of trial NCT06075810?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-11-09. Estimated completion is 2025-10-31.
What conditions does trial NCT06075810 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV.
What interventions are being tested in trial NCT06075810?
The interventions under investigation include: MBQ-167 (DRUG).
Who is sponsoring clinical trial NCT06075810?
This trial is sponsored by MBQ Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075810 being conducted?
This trial has 4 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.